Shots:

• Fractyl highlighted preclinical data of Rejuva pancreatic gene therapy candidate under the title, ‘Single-Dose GLP-1-Based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity’
• The preclinical data demonstrated a 42% decrease in the liver weight & 67% decrease in the liver triglyceride content vs PBO post 2mos.
• The data also showed a 36% reduction in total cholesterol & a 51% reduction in LDL cholesterol vs PBO post 2mos., suggesting GLP-1 PGTx candidate’s potential of minimizing cardiovascular risk due to increased cholesterol levels. The first GLP-1 PGTx candidate nomination for obesity is expected in H2’24 with further exploration in MASLD/MASH

Ref: Fractyl Health| Image: Fractyl Health

Related News:- The US FDA Grants IDE Approval to Fractyl Health for Initiating Remain-1 Trial of Revita to Treat Obesity

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com